Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Centessa Pharmaceuticals PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -928.13%, while the net margin is -875.79%. These profitability ratios, combined with a Return on Equity (ROE) of -60.62%, provide a clear picture of how effectively CNTA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CNTA competes directly with industry leaders such as LEGN and LQDA. With a market capitalization of $3.82B, it holds a leading position in the sector. When comparing efficiency, CNTA's gross margin of 100.00% stands against LEGN's 57.66% and LQDA's 94.16%. Such benchmarking helps identify whether Centessa Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.
